Form 8-K - Current report:
SEC Accession No. 0001193125-24-250223
Filing Date
2024-11-04
Accepted
2024-11-04 07:00:58
Documents
14
Period of Report
2024-11-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d904891d8k.htm   iXBRL 8-K 35803
2 EX-99.1 d904891dex991.htm EX-99.1 13421
  Complete submission text file 0001193125-24-250223.txt   183798

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kalv-20241104.xsd EX-101.SCH 2853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20241104_lab.xml EX-101.LAB 18757
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20241104_pre.xml EX-101.PRE 11712
16 EXTRACTED XBRL INSTANCE DOCUMENT d904891d8k_htm.xml XML 3775
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 241420725
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)